Our Story

Get to know our mission, vision, and core values.

Collaborating on all therapeutic modalities, Resolian fuses expertise from Alliance Pharma, Drug Development Solutions, and Denali Medpharma to provide worldwide access to proven scientific solutions.

We are an established and expanding global team of experts, resolute in our goal to offer an accessible, enhanced customer experience through a personalized approach and proactive management.

Mission

Accelerating drug development in close collaboration with our partners and creating a rewarding work environment.

Vision

Resolute in leading the global analytical solutions landscape.

Core Values

Integrity

Doing the right thing, even when no one's watching.

Customer Obsession

Relentlessly focused on exceeding customer expectations.

Passion

We are committed to the work we do and take pride in how we do it.

Stronger Together

Unity is our strength, enabling us to achieve more.

Financially Sustainable

Creating sustainable value that ensures our mutual success.

Leadership Team

Meet our team. 

 

Rob Stachlewitz

Chief Executive Officer

Linkedin
Read Bio

Patrick Bennett

Chief Business Officer

Linkedin
Read Bio

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin
Read Bio

Min Meng

Chief Operations Officer.
President of Resolian APAC

Linkedin
Read Bio

Alex Abramov

Chief Financial Officer

Linkedin
Read Bio

Timothy Sangster

Executive Director, Operations (UK)

Linkedin
Read Bio

Jason Wang

Site President (Australia)

Linkedin
Read Bio

Laixin Wang, Ph.D.

Site President (China)

Linkedin
Read Bio

Aihua Liu, Ph.D.

Executive Director (US) 

Linkedin
Read Bio

Ellen Stokvis

Operations Director, Analytical Sciences

Linkedin
Read Bio

For the latest news, visit our LinkedIn

Visit LinkedIn

Visit our Events page

Visit Events

Copyright © 2024 Resolian Inc. All rights reserved.

Scroll to Top

Rob Stachlewitz

Operations Director, Analytical Sciences

Linkedin

Rob has over 25 years of pharmaceutical development and laboratory operations management experience. He has led large, multinational operations groups supporting analytical services and large sites supporting nonclinical toxicology and analytical services. Rob has seen the contract laboratory business from both sides as an outsourcing manager for a large pharmaceutical client and a senior executive in a contract research organization. His pharmaceutical development experience includes roles within Abbott Laboratories and Boehringer Ingelheim. Prior to joining Resolian, Rob was a Vice President in Safety Assessment for Charles River. He is passionate about getting new medicines to the patients that need them.

Rob earned his B.S. Degree in Biology and Teaching from Michigan State University and his Ph.D. In Pharmacology from the University of North Carolina at Chapel Hill. Rob is also a Diplomate of the American Board of Toxicology.

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.

 

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Min Meng

President of Resolian APAC

Linkedin

Min Meng received her Ph.D. in biomedicinal chemistry from the School of Pharmacy, University of Maryland followed by a postdoctoral fellowship at the American Health Foundation focusing on the carcinogenic toxicity of tobacco smoke using technologies like LC-UV, GC-MS/MS, and LC–MS/MS. From 1998 to 2017, she worked at Tandem Labs/LabCorp/Covance, a bioanalytical CRO, in roles ranging from scientist to lab director and technical director.

In 2017, Meng returned to her hometown and established Denali Medpharma, a leading bioanalytical CRO in Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, where Dr. Meng is currently the chief operating officer and president of the Asia Pacific region. 

Alex Abramov

Chief Financial Officer

Linkedin

Alex Abramov has held various finance and operations leadership roles at Labcorp, Covance, Eurofins and Byram Healthcare (O&M). Public companies and private equity experience. Skilled in Corporate Finance, Global Expansion and Consolidation, M&A, FP&A, Integration, Business Reorganization and Medical Billing and Reimbursement.  

Working experience at Clinical Diagnostics, Pathology, Central and Clinical Trials Labs, Medical Devices Distribution (DME), Healthcare, CRO, Pharmaceuticals and other Life Sciences businesses. 

Timothy Sangster

Executive Director, Operations (UK)

Linkedin

A well-travelled experienced transformational executive who has led and expanded departments for the past 20 years. A well-rounded bioanalytical specialist with strong regulatory experience supporting Pharmaceutical development but also other areas of research throughout his career, giving a wide range of experience and knowledge. 

Fostering a culture of inclusiveness and support has led to great success so far; the biggest achievements to date are measured by the many other great careers that he has had the great pleasure to give support to and learn from along the way. Coaching and mentoring has always been a key driver for him and also some of his proudest achievements.


Jason Wang

Site President

Linkedin

Jason obtained his Ph.D. in Environmental Science in 2007 from New Jersey Institute of Technology. After graduation, Jason worked in a few leading bioanalytical CROs on the east coast of New Jersey and Pennsylvania before he took over as a manager in TetraQ, University of Queensland, Australia in 2013. In 2020, Jason took another role as senior director of Bioanalysis at Q Square Solutions, Beijing China, prior to joining Resolian Australia in early 2022 as Site President. 

Jason has over 15 years of experience in bioanalysis. From bench scientist to senior director, Jason acquired extensive knowledge and hands-on experience in bioanalytical method development, validation and sample analysis. He has expertise in both LC-MS/MS and Ligand binding assay, including immunogenicity. He is also very familiar with US FDA, EMA and NMPA regulations related to bioanalysis. 

 Jason also has over 8 years of management experience. During 7 years in TetraQ, Jason led the growth and expansion of TetraQ. 

Laixin Wang Ph.D.

Site President (China)

Linkedin

Laixin received his Ph.D of medicinal chemistry from the School of Pharmaceutical Sciences, Beijing Medical University. He conducted his postdoctoral training at the University of Utah and Duke University. Laixin has 20 years of experience in GLP bioanalysis and 7 years of experience in organic synthesis and drug formulation research and development. He specializes in the synthesis, formulation and bioanalysis of oligonucleotide drugs.

He is a member of the Nucleic Acid Drug Committee of Chinese Pharmaceutical Association. Before returning to China co-founded Chonging Denali Medpharma in 2017, he served as the vice president of NovaBioAssays and the technical director of Tandem Labs. He also worked as a senior scientist at Genta and Salus Biopharmaceuticals in the United States. He has obtained 3 US invention patents, published more than 30 SCI papers, more than 50 conference papers, and hosted 4 international academic conference trainings. 

Aihua Liu

Director, Bioanalysis

Linkedin

Dr. Liu received a Ph.D. in Analytical Chemistry, an M.S. in Pharmaceutical Chemistry, and a B.S. in Pharmacy. Before joining Resolian, she held senior positions at Alliance Pharma (Senior Director), Dyad Labs (Director), Covance/ LabCorp and Tandem Labs.

She is a seasoned expert in bioanalysis with over two decades of experience and her research interests focus on developing and validating innovative bioanalytical methods, as well as sample analysis. She specializes on oligonucleotides, ADCs, proteins, biomarkers, small molecules, and new modalities. Dr. Liu has authorized more than 85 conference posters/oral presentations and peer-reviewed publications.

Dr. Liu also has extensive experience in people management, team development, and process improvement, with a focus on fostering a collaborative and high-performing environment. By streamlining processes and empowering teams, Dr. Liu is able to inspire growth, innovation, and efficiency. This approach has consistently led to both individual development and overall organizational success.

 

Ellen Stokvis

Operations Director, Analytical Sciences

Linkedin

Ellen has over 20 years of experience in pharmaceutical analysis, starting her career in bioanalysis at the Cancer Institute in Amsterdam, the Netherlands. She moved to the UK and worked within GSK R&D and then at Quotient Bioresearch and LGC as Team Leader and Regulated Project Manager in bioanalytical LC-MS/MS. Ellen then moved into the Pharmaceutical and Healthcare Analysis area, where she became initially Team Leader for the GMP CMC team in Fordham. In that role she oversaw the expansion of the analytical service offering and increased the size and capacity of the team until in 2018, she became Operations Director of what now forms the Resolian Analytical Sciences division. 

Ellen holds a BSc and MSc in Chemistry and a Ph.D. in Pharmaceutical Analysis from Utrecht University, the Netherlands.